

FORM PTO-1390 (Modified)  
(REV 10-95)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

PRIN-0064

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/402405

INTERNATIONAL APPLICATION NO.  
PCT/US98/06615INTERNATIONAL FILING DATE  
10 April 1998PRIORITY DATE CLAIMED  
10 April 1997

## TITLE OF INVENTION

METHOD OF DETECTING PROCARBOXYPEPTIDASE A AND CARBOXYPEPTIDASE A LEVELS IN  
BIOLOGICAL FLUIDS

APPLICANT(S) FOR DO/EO/US

GILVARG, Charles

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ has been transmitted by the International Bureau.
  - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

## Items 13 to 18 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.  
A **SECOND** or **SUBSEQUENT** preliminary amendment.
16. ☐ A substitute specification.
17. ☐ A change of power of attorney and/or address letter.
18. ☐ Certificate of Mailing by Express Mail
19. ☒ Other items or information:

## Executed Verified Statement Claiming Small Entity Status

"Express Mail" Label No. EL429957862US

Date of Deposit - 4 October 1999

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Box PCT Washington, D.C. 20231.

By Suzanne Sparkman  
Typed Name: Suzanne Sparkman

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.53) <b>09/402405</b>	INTERNATIONAL APPLICATION NO. <b>PCT/US98/06615</b>	ATTORNEY'S DOCKET NUMBER <b>PRIN-0064</b>
--	--	--

20. The following fees are submitted: .

**BASIC NATIONAL FEE ( 37 CFR 1.492 (a) (1) - (5) ) :**

- ☐ Search Report has been prepared by the EPO or JPO ..... **\$840.00**
- ☒ International preliminary examination fee paid to USPTO (37 CFR 1.482) ..... **\$670.00**
- ☐ No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) ..... **\$760.00**
- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... **\$970.00**
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) ..... **\$96.00**

**ENTER APPROPRIATE BASIC FEE AMOUNT =****\$670.00**

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

**\$0.00**

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	5 - 20 =	0	x \$18.00
Independent claims	5 - 3 =	2	x \$78.00
Multiple Dependent Claims (check if applicable).			<input type="checkbox"/>

**\$0.00****\$156.00****\$0.00****TOTAL OF ABOVE CALCULATIONS =****\$826.00**

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).

☒**\$413.00****SUBTOTAL =****\$413.00**

Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

**\$0.00****TOTAL NATIONAL FEE =****\$413.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).

☒**\$40.00****TOTAL FEES ENCLOSED =****\$453.00**

Amount to be:  
refunded

\$

charged

\$

- ☒ A check in the amount of **\$453.00** to cover the above fees is enclosed.
- ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \_\_\_\_\_ to cover the above fees.  
A duplicate copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **12-1086** A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

**LICATA, Jane Massey**  
**Law Offices of Jane Massey Licata**  
**66 E. Main Street**  
**Marlton, New Jersey 08053 US**  
**865-810-1515**

Jane Massey Licata  
 SIGNATURE

**Jane Massey Licata**  
 NAME

NAME

32,257

REGISTRATION NUMBER

4 October 1999  
 DATE

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY  
STATUS (37 CFR 1.9(f) AND 1.27 (d)) - NONPROFIT ORGANIZATION**

Docket No.  
PRIN-0064

Serial No.  
PCT/US98/06615

Filing Date  
10 April 1998

Patent No.

Issue Date

Applicant/ Charles Gilvarg  
Patentee:

Invention:

**Method of Detecting Procarboxypeptidase A and Carboxypeptidase A Levels in Biological Fluids**

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION: Princeton University

ADDRESS OF ORGANIZATION: Princeton, New Jersey 08544

TYPE OF NONPROFIT ORGANIZATION:

- ☒ University or other Institute of Higher Education
- ☐ Tax Exempt under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3))
- ☐ Nonprofit Scientific or Educational under Statute of State of The United States of America  
Name of State: \_\_\_\_\_ Citation of Statute: \_\_\_\_\_
- ☐ Would Qualify as Tax Exempt under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3)) if Located in The United States of America
- ☐ Would Qualify as Nonprofit Scientific or Educational under Statute of State of The United States of America if Located in The United States of America  
Name of State: \_\_\_\_\_ Citation of Statute: \_\_\_\_\_

I hereby declare that the above-identified nonprofit organization qualifies as a nonprofit organization as defined in 37 C.F.R. 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention described in:

- ☐ the specification to be filed herewith.
- ☒ the application identified above.
- ☐ the patent identified above.

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the above-identified nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed on the next page and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☒ no such person, concern or organization exists.  
☐ each such person, concern or organization is listed below.

FULL NAME

ADDRESS

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

FULL NAME

ADDRESS

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

FULL NAME

ADDRESS

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

FULL NAME

ADDRESS

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING:

TITLE IN ORGANIZATION:

ADDRESS OF PERSON SIGNING:

*Allen J. Smigelli*  
*Associate Professor*

Princeton University

SIGNATURE:

DATE:

*Allen J. Smigelli*

*9/27/09*

METHOD OF DETECTING PROCARBOXYPEPTIDASE A  
AND CARBOXYPEPTIDASE A LEVELS IN BIOLOGICAL FLUIDS

**Background of the Invention**

Determination of altered enzyme levels by measurement of  
5 enzyme activity in biological samples is used routinely by  
clinicians to assist in the diagnosis of a multitude of  
diseases or conditions wherein physical symptoms alone may not  
be definitive. However, the usefulness of such assays is  
dependent upon the specificity of the enzyme to the disease or  
10 condition and the sensitivity and selectivity of the enzymatic  
assay.

For example, acute pancreatitis is defined clinically as  
a discrete episode of symptoms caused by intrapancreatic  
activation of digestive enzymes. The cause of this activation  
15 is unknown; however, premature activation of zymogen to active  
enzymes within the pancreas results in autodigestion and  
inflammation of the pancreas. Symptoms include a steady, dull  
or boring pain in the epigastrium or left upper abdominal  
quadrant which is poorly localized and reaches peak intensity  
20 within fifteen minutes to one hour. The incidence of acute  
pancreatitis is difficult to ascertain as uniform diagnostic  
criteria and effort have not been applied. However, there is  
an urgency in accurately diagnosing acute pancreatitis to  
exclude other acute conditions that require different, usually  
25 surgical, management such as perforated peptic ulcer, acute  
cholangitis, appendicitis and mesenteric infarction. In  
contrast, pancreatitis is best treated through a "hands off"  
approach of eliminating food intake and increasing hydration.

- 2 -

Determination of serum amylase activity is the test most frequently used for the diagnosis of acute pancreatitis. The frequent use of this test undoubtedly stems from the ease in obtaining substrate and performing the spectrophotometric analysis. In addition, the cost is significantly less as compared to an ultrasound or CT scan. However, results from this assay are difficult to interpret with any certainty due to the extensive distribution and background levels of amylase throughout the body. Pancreatic amylase only accounts for approximately 40% of the amylase found in serum. In fact, many individuals experience hyperamylasia for reasons unrelated to pancreatic pathology such as salivary diseases, gut diseases, liver diseases and other conditions such as renal failure, thermal burns, alcoholism, postoperative state, ketoacidosis, fallopian or ovarian cysts, pneumonia, anorexia and abdominal aortic aneurysm. (Pieper-Bigelow et al. (1990) *Gastroenterol. Clin. North Am.* 19:793-810).

Sensitivity of the amylase test is also suspect, in part, because of the short half-life of the enzyme relative to others produced in the pancreas. With a half-life of only two hours, amylase is the first enzyme to return to normal levels (Ventrucci et al. (1987) *Pancreas* 2:506-509) resulting in a sensitivity of only 33% two days after an initial bout of pancreatitis (Winslet et al. (1992) *Gut* 33:982-986).

Further, even in cases where pancreatic disease is known to be present, there is no correlation between the severity of pancreatitis and the level of serum amylase.

Accordingly, a number of digestive enzymes produced by the pancreas have been considered as possible alternatives to amylase.

Carboxypeptidase A (CPA) is a digestive enzyme synthesized exclusively by the pancreas as a zymogen precursor, procarboxypeptidase A (PCPA). Significant levels of CPA have been detected in serum of those suffering from acute pancreatitis, while healthy individuals have little (Roth, M. and Rohner, A. (1983) *Clin. Chim. Acta.* 135:65-71; Kazmierczak, S.C. and Van Lente, F. (1989) *Clin. Chem.* 35:251-255) to no (Peterson et al. (1982) *Anal. Biochem.* 125:420-426; Brown et

- 3 -

al. (1987) *Anal. Biochem.* **161**:219-225) detectable amounts of the enzyme. Several substrates and a variety of assay procedures have been proposed for the determination of the pancreatic enzyme CPA. Such assays include UV spectrophotometry to directly monitor the cleavage of the peptide bond, and colorimetric and fluorometric methods to measure the amino acid released from the C-terminus. (Bergmeyer, H.U., Ed. (1974) *Methods of Enzymatic Analysis*, Vol. 2, 2nd ed., Academic Press, New York; Roth, M. and Rohner, A. (1983) *Clin. Chim. Acta* **135**:65-71). More frequently used substrates include N-benzyloxycarbonyl-glycyl-L-phenylalanine (Z-Gly-Phe) and hippuryl-phenylalanine (Bz-Gly-L-Phe). An assay involving the determination of the  $\alpha$ -naphthol released from the N-terminal blocking group in naphthoxycarbonyl-phenylalanine has also been disclosed. (Ravin, H.A. and Seligman, A.M. (1951) *J. Biol. Chem.* **190**:391-402). In addition, a spectrophotometric assay employing N-(2-furanacryloyl)-L-Phe-L-Phe (FAPP) has been reported. (Peterson et al. (1982) *Anal. Biochem.* **125**:420-426). However, while the FAPP substrate had the best kinetic constants of any CPA substrate to date, its modest change in absorbance at 330 nm ( $\epsilon=2000$ ) and the high initial absorbance at that wavelength ( $\epsilon=9350$ ) significantly reduce the sensitivity and precision of this assay.

A new class of synthetic peptides suitable for assaying peptidase activity was described by Kingsbury et al. (1984) *Proc. Nat'l Acad. Sci. USA* **81**:4573-4576. These peptides contain amino acid mimetics with nucleophilic substitutions at the  $\alpha$ -carbon of glycine residues. The amino acid mimetics are stable when the nitrogen lone pair electrons are delocalized, as they are in a peptide bond, and release of the amino acid mimetic results in its decomposition to generate the nucleophilic substituent. If the substituent is linked to the glycine residue through sulfur, decomposition yields a compound with a free sulfhydryl group. Its appearance can be monitored spectrophotometrically in the presence of Ellman's reagent which reacts rapidly and quantitatively with free sulfhydryl groups to form a highly colored anionic species that absorbs

- 4 -

at 412 nm. (Ellman, G.L. (1959) *Arch. Biochem. Biophys.* **82**:70-77). An assay for measuring CPA in serum with the N-blocked phenylalanine substrate, N-acetyl-phenylalanyl-L-3-thiaphenylalanine was developed. (Brown et al. (1987) *Analytical Biochemistry* **161**:219-225). However, use of an assay measuring CPA activity to diagnose acute pancreatitis has been debated.

Using p-OH Bz Gly Phe as a CPA substrate, Kazmierczak and Van Lente carried out an extensive study comparing CPA, amylase and lipase levels as indicators of acute pancreatitis. A major difficulty for CPA was their finding that patients with renal insufficiency, but without pancreatitis, appeared to have elevated levels of the enzyme. Kazmierczak and Van Lente also found the diagnostic sensitivity of the three assays to be comparable at cutoff values of 3 (23  $\mu\text{g/L}$ ), 185 and 300 U/L, respectively. They concluded that automated analysis for CPA activity, even in the absence of interferences, does not add to the diagnostic information provided by the widely available assays for amylase and lipase activity. (Kazmierczak, S.C. and Van Lente, F. (1989) *Clin. Chem.* **35**(2):251-5). High levels of CPA were also reported to be present in normal serum by Roth, M. and Rohner, A. (1983) *Clin. Chim Acta* **135**:65-71. Both groups found the average value of putative CPA in normal sera to be approximately 3.9  $\mu\text{g/L}$ .

Pancreatic cancer is even more difficult to diagnose than acute pancreatitis, resulting in an abysmal mortality rate since individuals frequently seek treatment only after the disease has reached advanced stages which are accompanied by pain, weight loss and jaundice. The cancer is rarely diagnosed in its initial stages, in part because no cost-effective, non-invasive diagnostic test exists to date. While ultrasonography, CT scans and endoscopic retrograde cholangiopancreatography can confirm the presence of pancreatic cancer, these procedures are too expensive to use for general screening and are normally not applied until too late. Attempts to discover a marker for pancreatic cancer have been hindered by the fact that little is known about risk factors which would predispose individuals to the cancer. However, a



- 5 -

number of individuals with pancreatic cancer have been reported to demonstrate high PCPA serum levels with normal amounts of CPA. Accordingly, determination of elevated levels of PCPA may serve as an early screen for this disease which has the lowest survival rate of any cancer. Like CPA, however, attempts to measure PCPA in serum have produced conflicting results.

Trypsin can fully activate PCPA in a concentration-dependent manner. It has been reported that 2 mg of trypsin per ml of serum can produce maximum activity of CPA in thirty minutes, although half as much trypsin required 120 hours. Amounts less than 0.5 mg per ml showed no detectable activation. (Peterson, L.M. and Holmquist, B. (1983) *Biochemistry* 22:3077-3082). These values are different from other studies, however, wherein maximum activity was obtained with 1 mg trypsin per ml of serum (Brown, K.S. Senior Thesis, Princeton University 1986).

Accordingly, there is a need for more sensitive and definitive enzymatic assays to diagnose diseases such as acute pancreatitis and pancreatic cancer in patients.

## 20 Summary of the Invention

An object of the present invention is to provide a method of enhancing the sensitivity and specificity of an assay measuring enzymatic activity in a sample which comprises measuring enzymatic activity in the sample in the presence and absence of a specific inhibitor of the enzymatic activity.

Another object of the present invention is to provide a method of measuring carboxypeptidase A levels in biological fluids which comprises contacting a biological fluid with a carboxypeptidase A substrate in the presence and absence of a carboxypeptidase A specific inhibitor and measuring changes in optical density resulting from hydrolysis of the carboxypeptidase A substrate by carboxypeptidase A in the presence and absence of the carboxypeptidase A specific inhibitor.

Another object of the present invention is to provide a method of diagnosing acute pancreatitis in a patient comprising detecting elevated levels of carboxypeptidase A in a biological

- 6 -

fluid of a patient using a carboxypeptidase A substrate, the specificity of which is enhanced by addition of a carboxypeptidase A specific inhibitor.

Yet another object of the present invention is to  
5 provide a method of measuring total carboxypeptidase A levels, including both carboxypeptidase A and procarboxypeptidase A in a biological fluid which comprises converting any procarboxypeptidase A in the biological fluid to carboxypeptidase A by addition of clostripain; contacting the  
10 biological fluid with a carboxypeptidase A substrate in the presence and absence of a carboxypeptidase A specific inhibitor; and measuring changes in optical density resulting from hydrolysis of the carboxypeptidase A substrate by carboxypeptidase A in the presence and absence of the  
15 carboxypeptidase A specific inhibitor.

Yet another object of the present invention is to provide a method of diagnosing pancreatic cancer in a patient which comprises detecting elevated levels of total carboxypeptidase A in a biological fluid of a patient by  
20 converting any procarboxypeptidase A in the biological fluid to carboxypeptidase A by addition of clostripain and contacting the biological fluid with a carboxypeptidase A substrate, the specificity of which is enhanced by addition of a carboxypeptidase A specific inhibitor, and contrasting the  
25 total carboxypeptidase level with an amount of carboxypeptidase A in the sample determined in the absence of clostripain so that elevated levels of procarboxypeptidase A indicative of early stage pancreatic cancer can be determined.

### 30 Detailed Description of the Invention

It has now been found that the sensitivity and specificity of enzymatic assays can be enhanced by utilization of blanks containing an inhibitor specific to the enzyme. For example, the pancreatic enzyme carboxypeptidase A was first  
35 characterized by Anson in 1937. (Anson, M.L. (1937) *J. Gen. Physiol.* 20:663). N-acetyl-phenylalanyl-L-3-thiaphenylalanine is a specific substrate for carboxypeptidase A (CPA) and has been proposed as a replacement for the amylase assay in

- 7 -

diagnosing pancreatitis. (Brown et al. (1987) *Analytical Biochemistry* 161:219-225). However, the extraneous optical density changes associated with its application to serum determinations limited sensitivity and reproducibility of this assay. Further, the question of high CPA baseline levels in the serum of healthy subjects has been raised which is critical to diagnostic use of the assay as it directly reflects upon the sensitivity in which a particular assay is capable of assessing pancreatic pathology.

It has now been demonstrated that the sensitivity and specificity of an assay measuring levels of carboxypeptidase A (CPA) in a biological fluid by addition of a CPA substrate is enhanced by utilization of a blank containing a CPA specific inhibitor. In a preferred embodiment of this CPA assay, the biological fluid comprises plasma or serum. However, it is believed that this assay could also be used to determine CPA levels in other biological fluids such as urine. Addition of CPA specific inhibitors  $\alpha$ -benzylsuccinic acid or potato CPA inhibitor (CPI) to CPA assays with the substrate N-acetyl-phenylalanyl-L-3-thiaphenylalanine (NACPSP) was found to correct for all extraneous changes in optical density (O.D.) resulting from decomposition of the substrate or reagents. By addition of these specific inhibitors to the blank, it is now possible to specifically measure the changes in optical density resulting from the low amount of CPA, i.e., 0.3  $\mu\text{g/L}$ , in normal human serum. Accordingly, an assay measuring enzymatic hydrolysis of a CPA substrate, preferably NACPSP in the presence and absence of a CPA specific inhibitor, can now be used to reproducibly detect CPA levels in biological fluids and in diagnosing acute pancreatitis.

In this assay, hydrolysis of the CPA substrate is measured using Ellman's reagent. Ellman's reagent reacts rapidly and quantitatively with free sulfhydryl groups to form a highly colored anionic species that absorbs at 412 nm. (Ellman, G.L. (1959) *Arch. Biochem. Biophys.* 82:70-77). However, neither the substrate nor Ellman's reagent used to measure hydrolysis of the substrate are completely stable compounds. Accordingly, decomposition of these compounds

- 8 -

results in an increase in O.D. during the assay. In addition, the half-Ellman which is liberated by the interaction of the Ellman's reagent with serum albumin is subject to reoxidation which causes a decrease in O.D. These effects are quite modest for ordinary analytical purposes. For example, substrate breakdown is 0.63 percent per hour at 37°C. However, the O.D. increases attributable to the minute amount of CPA in the serum of healthy individuals is so small that these ancillary O.D. changes can be dominating. Further, a blank containing Ellman's reagent and substrate only does not compensate for the reoxidation. Alternatively, a blank containing serum and Ellman's reagent does not compensate for substrate breakdown. In the assay of the present invention, however, wherein a specific CPA inhibitor is added to the blank, all extraneous O.D. changes are corrected. In the manual assay described below, the CPA specific inhibitor is prepared in a concentrated solution so that only a very small volume is required thus rendering any pipetting error in dispensing it to have an inappreciable effect on concentration relationships.

Accordingly, the present invention provides a diagnostic assay for pancreatitis by measuring levels of CPA in a biological fluid such as serum using a CPA substrate, preferably NAcPSP. As will be obvious to those of skill in the art, however, CPA substrates with a similar Michaelis constant,  $V_{max}$ , and extinction coefficient to NAcPSP can also be used. The specificity of the substrate for the enzyme is enhanced by addition of a CPA specific inhibitor to the blank. For example, FAPP has been disclosed to produce such modest changes in absorbance that the sensitivity and precision of an assay measuring CPA in serum is significantly reduced. However, addition of a CPA specific inhibitor to the blank of this assay increased the sensitivity and precision such that FAPP is a useful substrate for determination of CPA levels in serum with the method of the present invention. Examples of CPA specific inhibitors which can be used include, but are not limited to,  $\alpha$ -benzylsuccinic acid ( $K_i = 1 \mu M$ ) and CPI. Monoclonal antibodies raised against the enzyme in accordance with well known methods can also be used as specific inhibitors in the

- 9 -

assay. By adding a specific enzyme inhibitor to the assay blank, only optical density changes attributable to enzymatic cleavage of the substrate are measured. Assays are performed in pairs with the inclusion of a sufficient concentration of inhibitor in the second cuvette to eliminate at least 99 percent of any CPA activity and to correct for extraneous O.D. changes in normal serum thus making it possible to accurately detect CPA levels in serum of healthy adults. Assays can be performed by a manual method or in a Cobas Bio centrifugal analyzer (Roche Diagnostics Systems, Branchburg, NJ) at 37°C.

Stability of CPA activity during the time period for the assay of the present invention was confirmed. In these experiments, sera from two individuals was assayed and monitored spectrophotometrically every hour over a period of six hours. Absorbance increased in a linear fashion for both samples, thus indicating that CPA activity was in fact being monitored and that it was stable at 37°C for this time period, which is actually twice as long as the standard assay. These studies also indicate that, while incubation for three hours is preferred, activity after only a one hour incubation period provides an accurate estimate of CPA activity for diagnostic purposes since CPA activity, on average, is linear throughout the incubation period. Further, experiments in serum from four different individuals demonstrated a linear increase in  $\Delta OD$  which correlated with serum concentrations.

Specificity of the assay for CPA and not PCPA was also confirmed. In these experiments, three different samples were tested for CPA activity using either  $\alpha$ -benzylsuccinic acid or CPI, an inhibitor that does not bind to PCPA. Both inhibitors were added at concentrations sufficient to eliminate at least 99% of all CPA activity. In two of the samples from healthy individuals, CPA activity was approximately equivalent with the two inhibitors. The third sample, which was known to have approximately 250 times more PCPA than CPA, also yielded similar results with the two inhibitors.

Reproducibility of the assay of the present invention was determined in sera from two individuals by performing

- 10 -

numerous assays on specific serum samples. Analysis of three samples from each individual revealed that CPA activity measurements were reproducible for both a given serum and among different samples for a given individual. Results from these experiments are depicted in Table 1. Enzyme activity is expressed in U/L.

TABLE 1

Serum #1	Trials	Mean	+2S
set 1	10	0.098	0.030
set 2	11	0.098	0.037
set 3	9	0.109	0.040
Serum #2	Trials	Mean	+2S
set 1	9	0.058	0.022
set 2	9	0.046	0.014
set 3	14	0.042	0.024

Variability of CPA activity measurements for a single sample is believed to be largely attributable to the reproducibility of the spectrophotometric determination in view of the exceedingly high levels of sensitivity at which CPA is being measured. Mean CPA activity varied somewhat among samples drawn at different times from a given individual, although all sets overlap within error demonstrating that a healthy individual does not experience wide fluctuations in serum CPA levels.

Having established the selectivity and reproducibility of this assay, a larger study was performed on 108 samples of plasma collected from healthy blood donors. Using the standard assay described in Example 2 with 0.1 ml serum per ml of solution, the CPA level of each sample was determined. CPA activities were distributed somewhat asymmetrically although they approximated a normal distribution with a mean of  $0.068 \pm 0.055$  U/L ( $\bar{X} \pm 2S$ ) and a median of 0.064 U/L.

CPA activities in males and females, analyzed independently, had similar distributions. Of the 108 samples, 62 were taken from males with an in-class mean of  $0.071 \pm 0.057$

- 11 -

U/L ( $X \pm 2S$ ) and median of 0.068, while 46 females had a mean of  $0.063 \pm 0.050$  U/L ( $X \pm 2S$ ) and a median of 0.057 U/L. Further analysis of the data revealed no correlation between CPA levels and age of the donors (ranging from 21 to 79 years).

5        The baseline of the assay of the present invention is approximately 58 fold less than that reported by Kazmierczak and Van Lente as a cutoff (Kazmierczak, S.C. and Van Lente, F. (1989) *Clin. Chem.* **35**(2):251-5). Thus, the assay of the present invention is much more sensitive than the CPA assay  
10    taught by Kazmierczak and Van Lente to probably not be "warranted" in diagnosing pancreatitis. Further, elevated levels of CPA observed by Kazmierczak and Van Lente in patients suffering from renal insufficiency have recently been found to be attributable to a several fold elevation in the proenzyme  
15    without any accompanying appearance of detectable CPA. Therefore, contrary to teachings in the prior art, the CPA assay of the present invention is useful in diagnosing pancreatitis.

      A number of patients were tested with this assay to  
20    assess levels of CPA activity during illness. Two main groups were studied: individuals diagnosed with pancreatitis and patients with nonpancreatic diseases. Tests on pancreatic serum were conducted with the automated assay described in Example 2. Elevations in serum CPA concentrations were  
25    observed in seven selected pancreatics with values as high as 1000 times above baseline. Tests on serum from patients with nonpancreatic conditions uncovered an enormous variety of disease states with elevated amylase but normal CPA levels.

      Accordingly, patients exhibiting symptoms of acute  
30    pancreatitis can be diagnosed quickly and easily using the assay of the present invention to detect elevated levels of CPA. Using this assay, normal CPA activities have been determined to have a range of  $0.068 \pm 0.083$  U/L ( $X \pm 3SD$ ). Accordingly, serum levels of CPA greater than 0.20 U/L are  
35    considered elevated and are indicative of pancreatitis.

      As will be obvious to those of skill in the art upon this disclosure, average CPA levels in other biological fluids

- 12 -

from healthy control populations such as plasma, saliva or urine can be routinely determined in accordance with these teachings and elevated CPA levels in these biological fluids can also be indicative of pancreatitis.

5 Further, while the focus of these experiments was upon enhancing the CPA assay, the addition of a specific inhibitor to the blank of an enzymatic assay can be used to enhance the accuracy and sensitivity of any enzyme assay. Various specific inhibitors for selected enzymes are known in the art and can  
10 be routinely added to blanks of assays for the selected enzymes in accordance with the teachings herein. Further, monoclonal antibodies against a selected enzyme which are also useful as specific inhibitor in the method of the present invention can be raised in accordance with well known techniques.  
15 Accordingly, the present invention provides a method for enhancing the sensitivity and specificity of any assay measuring enzymatic activity in a sample wherein enzymatic activity in the sample is measured in the presence and absence of a specific inhibitor of the enzymatic activity.

20 It has also been found that the CPA assay of the present invention can be modified to measure both CPA and PCPA, referred to herein as "total CPA", in a biological fluid. Several enzymes have been suggested for use in measuring levels of total CPA activity including bovine trypsin, subtilisin and  
25 urokinase, with bovine trypsin being preferred. (Peterson, L.M. and Holmquist, B. (1983) *Biochemistry* 22:3077-3082). However, attempts to optimize PCPA activation by trypsin by addition of combined reagents and soybean trypsin inhibitors after a short incubation indicate that trypsin activated serum  
30 does not reflect actual PCPA levels due to tryptic-induced degradation of CPA.

In the present invention, the protease clostripain was added to activate any PCPA in the biological fluid so that total CPA could be measured. Tests with sera from four healthy  
35 individuals and one with pancreatitis indicated that, unlike trypsin, supramaximal clostripain concentrations resulted in only slight CPA activity losses. Further, CPA activities after



- 13 -

clostripain activation were significantly higher than the maximum values that could be obtained when using trypsin.

Sixty-six samples previously tested for CPA activity were analyzed for total CPA activity following clostripain activation. Of these, two samples had exceedingly high levels of PCPA and were not analyzed further since they fell well outside the range of "normal" based upon calculations with the other samples. Overall, males (37) had a mean value for total CPA activity of  $1.50 \pm 0.82$  U/L ( $X \pm 2S$ ) while females (27) had a distribution of  $1.50 \pm 1.04$  U/L ( $X \pm 2S$ ).

Serum from patients with pancreatic cancer at various stages and patients with related conditions were analyzed for total CPA concentrations by the assay of the present invention wherein clostripain was first added to convert any PCPA to CPA. A detailed description of activation by clostripain is provided in Example 7. Data from these experiments are shown in Table 2.

Table 2

CPA and total CPA activity in patient  
with pancreatic cancer and related diseases

Patient	CPA (U/L)	Total CPA (U/L)	Ratio	Diagnosis
FLC	0.061	43.9	720	adenocarcinoma of head
TMa	0.008	6.99	874	adenocarcinoma (lymphatics)
S	0.126	5.61	45	adenocarcinoma
SSa	0.090	4.97	55	islet cell tumor
SSb	0.038	3.27	86	adenocarcinoma
VC	0.049	3.19	65	adenocarcinoma; head removed
RD	-	3.06	-	duodenal tumor with obstructed duct
TMb	0.037	1.70	46	cancer of the ampulla

- 14 -

Patient	CPA (U/L)	Total CPA (U/L)	Ratio	Diagnosis
SG	0.046	1.14	25	pancreatic tail tumor with duct polyps
GT	0.034	0.82	24	advanced, unresectable cancer
DJ	0.088	0.45	5	advanced adenocarcinoma

While cancer patients exhibited normal CPA levels, total CPA concentrations were well above normal for several individuals. Those patients who demonstrated the highest PCPA levels generally suffered from resectable, early stage cancer. In contrast, individuals with advanced stages of cancer (GT and DJ) had very low PCPA levels, with serum from DJ containing less PCPA (0.36 U/L) than any individual in the healthy population. Accordingly, elevated levels of PCPA determined by measuring total CPA using the assay of the present invention is believed to be useful as a marker in the diagnosis of early stage pancreatic cancer.

The following nonlimiting examples are provided to further illustrate the instant invention.

## EXAMPLES

### Example 1                      Materials

N-acetyl-phenylalanyl-3-thiaphenylalanine (NAcPSP) was obtained from Peptides International (Louisville, KY) and stored at room temperature in a desiccator. Bovine trypsin, clostripain, subtilisin, urokinase, N $\alpha$ -benzoyl-L-arginine p-nitroanilide (BAPNA), soybean trypsin inhibitor (STI), and bovine serum albumin were all obtained from Sigma Chemical Co. (St. Louis, MO) and stored over desiccant at 4°C. Ellman's reagent [5,5'-dithio-bis(2-nitrobenzoic acid)], DL-benzylsuccinic acid, and N-(3-[2-furyl]acryloyl)-phe-phe (FAPP) were also purchased from Sigma and stored at room temperature. Carboxypeptidase Potato Inhibitor (CPI) and dithiothreitol

- 15 -

(Cleland's Reagent) were obtained from Calbiochem (San Diego, CA) and stored over a desiccant at 4°C. All other chemicals were of analytical grade.

Solutions of NAcPSP, FAPP, Ellman's reagent,  $\alpha$ -benzylsuccinic acid, clostripain and bovine CPA were stored at -20°C. All other solutions were made on the day of the experiment and kept at 0°C.

Blood and plasma used to assess baseline CPA and PCPA levels was collected in three sets from blood donors at New York Hospital. Other blood samples were obtained from either the NYU Hospital or the McCosh Clinic at Princeton University. All samples were stored at -20°C.

Pancreatic juice was obtained from the externalized pancreatic duct in an otherwise healthy individual and stored at -20°C.

#### **Example 2                      Standard Assay for Measuring CPA activity in Human Serum**

CPA activity was determined by applying the substrate NAcPSP to a solution containing Ellman's reagent and serum and subsequently monitoring the production of the half Ellman's anion at 412 nm spectrophotometrically. This assay employed the following reactants at the indicated final concentrations: human serum (usually 0.1 ml per ml total solution); Ellman's reagent (0.5 mM); Tris buffer, pH 7.5, (0.2 M); NaCl (0.5 M); and NAcPSP (0.4 mM). Serum concentrations ranging from 0.003 to 0.15 ml of total solution were also applied. The total volume of the reactants was three ml.

The addition of Ellman's reagent to the serum was followed by a five minute incubation at 22°C, which allowed free sulfhydryl groups in the serum to react to completion with Ellman's reagent. After the addition of NAcPSP, one ml of this mixture was dispensed into each of two plastic cuvettes with one-cm path lengths. One of these cuvettes (referred to herein as the blank) contained one microliter of a CPA inhibitor (0.4 M in the case of benzylsuccinate) and the other cuvette (referred to herein as the test) contained a microliter of water. The cuvettes were then sealed and incubated at 37°C.

- 16 -

Absorbance was monitored every hour or hour and a half for a total of three hours with a Zeiss model PM6 spectrophotometer (Thornwood, NY).

This determination of CPA levels was based upon the difference in absorbance between the blank and the test cuvettes for a given sample and presented as units of activity per liter of serum in accordance with the following calculation. A unit is defined as one micromole of half-Ellman's anion produced per minute. Since Ellman's anion has a molar extinction coefficient of 13,600 L/Mol-cm at 412 nm, the production of one  $\mu$ mole per ml of solution results in an increase in absorbance of 13.6.

$$\begin{aligned} 1 \text{ U/L} &\approx (1 \mu\text{mole/min})/\text{L serum} \\ &\approx (13.6 \Delta\text{OD/min})/\text{L serum} \\ &\approx (0.00136 \Delta\text{OD/min})/0.1 \text{ ml serum} \end{aligned}$$

After 3 hours, the change in absorbance is 0.245 relative to a blank with no CPA activity for 1 U/L with the standard assay.

An automated assay using the Cobas Bio analyzer was also performed wherein a first set of determinations was made without the inhibitor. A second set was then made wherein the substrate solution contained the inhibitor. In the automated assay, the analyzer was set to provide for a five minute reaction time of the Ellman Reagent with the serum after which substrate was added and optical density determinations were made every 10 seconds for five minutes at a wavelength of 412 nm.

### **Example 3                      Determination of Kinetic Constant of CPA substrates**

Kinetic constants of serum CPA were determined for NAcPSP by utilizing the standard procedure and modifying the concentration of substrate within the range of 0.1 to 0.8 mM. Experiments were also performed using bovine CPA, pancreatic juice, and pseudocyst fluid, with each applied in concentrations high enough so that initial velocity calculations could be made following change in absorbance for two minutes. All CPA sources were additionally tested with FAPP in order to obtain values for  $K_m$  and relative velocities.

- 17 -

Assays of FAPP hydrolysis involved the addition of enzymes to solutions containing FAPP (0.02 to 0.2 mM) in a buffer of 50 mM Tris (pH 7.5) and 0.45 M NaCl. The reaction was followed at 330 nm using a Zeiss model PM6 spectrophotometer. At this wavelength the substrate has a high initial absorbance ( $\epsilon=9350$ ) which declines as the reaction proceeds ( $\Delta\epsilon=2000$ ). (Peterson et al. (1982) *Anal. Biochem.* **125**:420-426).

Lineweaver-Burke analysis was used to evaluate Michaelis constants for CPA with the two substrates. Independent confirmation of these constants for FAPP were made using competitive inhibition analysis. NACPSP hydrolysis was allowed to proceed following introduction of CPA for one minute, at which point a small, concentrated volume of FAPP was added to the solution. The change in velocity which resulted was used to calculate a  $K_i$  of FAPP against NACPSP.

#### Example 4 Comparison of CPA Inhibitors

Solutions of  $\alpha$ -benzylsuccinic acid with a reported  $K_i$  of 1  $\mu$ M and 1.6  $\mu$ M (Byers, L.D. and Wolfenden, R. (1973) *Biochemistry* **12**:2070-2078; Peterson et al. (1976) *Biochemistry* **15**:2501-2508), and Carboxypeptidase Potato Inhibitor (CPI), with a reported  $K_i$  of 5 nM (Hass, G.M. and Ryan, C.A. (1980) *Biochem. Biophys. Res. Commun.* **97**:1481-1486) were prepared such that each solution had similar efficiency at eliminating CPA activity as determined by their ability to arrest the activity of 50 ng bovine CPA assayed using the standard procedure described in Example 2. Final concentrations of the 1  $\mu$ l addition of the two solutions were 0.4 M for  $\alpha$ -benzylsuccinic acid and 1.4 mM for CPI. To compare their effectiveness in eliminating serum CPA activity, an identical amount of each inhibitor solution was added to two sets of three different serum samples, which were assayed by the standard procedure.

Further tests were also performed with  $\alpha$ -benzylsuccinic acid at different concentrations. In these tests, a higher volume of inhibitor solution applied to the blank cuvette was always paralleled with an identical increase in water added to the test cuvette.

- 18 -

**Example 5            Bovine Trypsin Activity in Normal and Serum  
                         Titrated Solutions**

Activities of bovine trypsin solutions were assessed by monitoring the hydrolysis of N-benzoyl-Arg-p-nitroanilide (BAPNA) at 406 nm with a Zeiss model PM6 spectrophotometer. BAPNA was used at a final concentration of 0.2 mM in 10 mM Tris buffer (pH 8.0). Following the addition of specified amounts of trypsin to the substrate solution, absorbance was followed over a period of two minutes with readings taken every 15 seconds. The procedure was used to determine activity of pancreatic juice, human serum, human serum spiked with bovine trypsin, and clostripain.

Slight modifications of this protocol were made when testing for trypsin activity in the presence of serum. NaCl, Tris buffer (pH 8.0), and BAPNA at a final concentration of 0.5 M, 6 mM, and 0.2 mM, respectively, were added to a plastic cuvette containing 0.025 ml of serum for a total volume of 1 ml. A concentrated trypsin solution (5 mg trypsin/ml 10 mM Tris buffer, pH 8.0) was added to the mixture in amounts ranging from 0.4 to 4 mg trypsin per ml serum. Absorbance was monitored spectrophotometrically at 406 nm every fifteen seconds for three minutes.

**Example 6            Activation of PCPA in human serum with trypsin**

Activation of PCPA with bovine trypsin was performed in accordance with methods described by Peterson, L.M. and Holmquist, B. (1983) *Biochemistry* 22:3077-3082. Bovine trypsin was dissolved in 10 mM Tris buffer (pH 8.0) and added to provide a final concentration of 0.5 to 6 mg/ml serum. Following a thirty minute incubation at 37°C, total CPA activity was determined using the standard assay described in Example 2. Similar experiments were performed wherein PCPA was activated with subtilisin and urokinase.

Alternatively, trypsin was added after all other reagents had been added to the serum to provide substrate enhanced protection for the CPA. More specifically, trypsin was added after the addition of NAcPSP to the serum containing the Ellman's reagent. The mixture was then incubated for five

- 19 -

minutes at 37°C at which time soybean trypsin inhibitor (STI) was added in sufficient quantity (approximately 2 mg STI/5 mg trypsin) to eliminate all bovine trypsin activity. Following this step, the solution was separated into two cuvettes as described in Example 2 and monitored at 412 nm for 3 hours with a Zeiss model PM6 spectrophotometer.

**Example 7<sup>1</sup>                      Activation of PCPA in Human Serum with Clostripain**

Approximately 3 mg (500 units) of lyophilized clostripain was dissolved in 1 ml of 10 mM Tris buffer (pH 8.0) along with  $\text{CaCl}_2$  and Cleland's Reagent at final concentrations of 20 mM and 1 mM, respectively. This mixture was incubated at room temperature for approximately 2 hours. This solution was then added to serum in concentrations ranging from approximately 50 to 500 units of clostripain/ml of serum. One unit was defined as the amount of clostripain which could cleave one micromole of N $\alpha$ -benzoyl arginine ethyl ester (BAEE) in one minute. Determination of PCPA levels in blood donor samples was performed with 250 units of clostripain per ml serum. The standard serum volume was 0.013 ml serum per ml total solution. This mixture was incubated for five minutes at 37°C, after which time Ellman's Reagent was added at the standard concentration to eliminate clostripain as it quickly derivatizes all sulfhydryl groups in the mixture. From this point, the standard assay as described in Example 2 was followed.

- 20 -

**What is claimed is:**

1. A method of enhancing sensitivity and specificity of an assay measuring enzymatic activity in a sample comprising measuring enzymatic activity in the sample in the presence and  
5 absence of a specific inhibitor of the enzymatic activity.

2. A method of measuring carboxypeptidase A levels in a biological fluid comprising:

(a) contacting a biological fluid with a carboxypeptidase A substrate in the presence and absence of a  
10 carboxypeptidase A specific inhibitor; and

(b) measuring changes in optical density resulting from hydrolysis of the carboxypeptidase A substrate by carboxypeptidase A in the biological fluid in the presence and absence of the carboxypeptidase A specific inhibitor.

15 3. A method of diagnosing acute pancreatitis in a patient suspected of suffering from acute pancreatitis comprising:

(a) measuring carboxypeptidase A levels in a biological fluid from a patient by detecting changes in optical density  
20 resulting from hydrolysis of a carboxypeptidase A substrate by any carboxypeptidase A in the biological fluid in the presence and absence of a carboxypeptidase A specific inhibitor; and

(b) determining whether the measured levels of carboxypeptidase A in the biological fluid of the patient are  
25 elevated over levels in biological fluid from a healthy control population.

4. A method of measuring total carboxypeptidase A levels in a biological fluid comprising:

(a) converting any procarboxypeptidase A in a  
30 biological fluid to carboxypeptidase A by addition of clostripain;

(b) contacting the biological fluid with a carboxypeptidase A substrate in the presence and absence of a carboxypeptidase A specific inhibitor; and



- 21 -

(c) measuring changes in optical density resulting from hydrolysis of the carboxypeptidase A substrate by carboxypeptidase A in the biological fluid in the presence and absence of the carboxypeptidase A specific inhibitor.

5           5. A method of diagnosing early stage pancreatic cancer in a patient comprising:

(a) converting any procarboxypeptidase A in a biological fluid obtained from a patient to carboxypeptidase A by addition of clostripain;

10           (b) measuring total carboxypeptidase A levels in the biological fluid by detecting changes in optical density resulting from hydrolysis of a carboxypeptidase A substrate by any carboxypeptidase A in the biological fluid in the presence and absence of a carboxypeptidase A specific inhibitor; and

15           (c) determining whether the measured levels of total carboxypeptidase A in the biological fluid of the patient are increased as compared to total carboxypeptidase A levels in a healthy population due to elevated procarboxypeptidase A in the biological fluid.

Docket No.  
PRIN-0064

# Declaration and Power of Attorney For Patent Application

## English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**Method of Detecting Procarboxypeptidase A and Carboxypeptidase A Levels in Biological Fluids**

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on 10 April 1998 as United States Application No. or PCT International Application Number PCT/US98/06615 and was amended on \_\_\_\_\_

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

60/041,835

(Application Serial No.)

10 April 1997

(Filing Date)

60/055,495

(Application Serial No.)

12 August 1997

(Filing Date)

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Status)  
(patented, pending, abandoned)

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Status)  
(patented, pending, abandoned)

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Status)  
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

3 Jane Massey Licata, Reg. No. 32,257  
 Kathleen A. Tyrrell, Reg. No. 38,350  
 Laura Plunkett, Reg. No. P-45,015

Send Correspondence to:

Law Offices of Jane Massey Licata  
66 E. Main Street  
Marlton, New Jersey 08053

Direct Telephone Calls to: (name and telephone number)

Jane Massey Licata 856-810-1515

Full name of sole or first inventor

Charles Gilvarg X

Sole or first inventor's signature

Charles Gilvarg

Date

9/28/99

Residence

240 Hartley Avenue, Princeton, New Jersey 08540 NJ

Citizenship

United States

Post Office Address

same as above

Full name of second inventor, if any

Second inventor's signature

Date

Residence

Citizenship

Post Office Address